Fri, Jul 3, 2026
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Alternative Market Briefing

Performance: 788 China Fund Ltd. down YTD -57% after +114% in 2007, Healthcare hedge fund Accipiter Life Sciences II loses 40% in March, Platinum Grove suffers worst performance since inception in March

Friday, April 11, 2008

Opalesque Exclusive: 788 China Fund Ltd. down YTD -57% after +114% in 2007 The 788 China Fund Ltd., which had past annual gains of +33.28% (2006) and +114.82% (2007), began 2008 with a January loss of -39.55% and after a brief February bounce back of +7.63% estimates March returns to be -33.91%. According to corporate documents the fund, managed by Jacques Mechelany, aims to achieve medium to long term growth by investing in Chinese and Chinese related financial markets.

According to these documents, "the Fund is designed to provide global investors with a unique vehicle through which to invest in China, with a favorably biased risk/reward ratio. Up to 80 % of the Fund will be invested through highly liquid indices, with constant stop losses and the ability to remain in cash during negative market trends.

Meanwhile, the Eurekahedge Greater China Hedge Fund Index is -4.65% for March as of today. Corporate website: Source

Healthcare hedge fund Accipiter Life Sciences II loses 40% in March From WSJ's MarketBeat: It has been one of the worst quarters for hedge funds in years. Just ask Gabe Hoffman. Mr. Hoffman, who focuses on healthcare stocks, saw a loss of 40.7% in March alone in his biggest fund, Accipiter Life Sciences II.

The Accipiter Life Sciences II is down 29% year to date, through April 4th, after last year’s 20.4% rise. His other fund, called Accipi......................

To view our full article Click here

Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Other Voices: Nvidia extraordinary growth and the challenge of sustaining demanding valuations over time[more]

    Antonio Di Giacomo, Senior Market Analyst at XS.com, writes: Nvidia has established itself as one of the most extraordinary growth companies in the global technology sector. Over the past two fiscal years, its revenues have risen from levels close to $60 billion annually to well above $120 billi

  2. Secondaries take center stage: What the 2026 PE landscape means for GPs and investors[more]

    Matthias Knab, Opalesque for New Managers: The 2026 edition of Dechert's Global Private Equity Outlook - "Signs of a Gradual Thaw" - marks a notable shift in industry sentiment. After years of compr

  3. And, finally: Time to share it with the people[more]

    From Newsoftheweird: Leavenworth, Washington, has become a tourist destination because of the Bavarian theme businesses have adopted there, NPR reported. One shop, the Leavenworth Nutcracker Museum, houses the world's largest nutcracker collection, thanks to 101-year-old Arlene Wagner. Wagner sta

  4. Opalesque Exclusive: Private Markets Evergreen Funds - An Insider's View[more]

    Matthias Knab, Opalesque for New Managers: Private Markets Evergreen Funds: What Investors Need to Know Before They Dive In The democratization of private markets is well underway. Structural barriers t

  5. Opalesque Exclusive: Governance, Scale, and Boutique Resilience in a Consolidating Hedge Fund Industry[more]

    Matthias Knab, Opalesque for New Managers: The hedge fund industry has undergone significant consolidation in recent years, with capital increasingly concentrated among large multi-strategy platforms. Yet boutique m